8-KMaterial AgreementsOther EventsExhibits & Filings

THERMO FISHER SCIENTIFIC INC. 8-K Report, Material Agreement (Dec 5, 2023)

Filed December 5, 2023For Securities:TMO

Summary

Thermo Fisher Scientific Inc. (TMO) has filed an 8-K report detailing a significant debt issuance. On December 5, 2023, the company successfully raised approximately $2.5 billion in aggregate principal amount through the public offering of senior notes across three tranches: $1 billion of 5.000% Senior Notes due 2026, $1 billion of 5.000% Senior Notes due 2029, and $500 million of 5.200% Senior Notes due 2034. These notes are general unsecured obligations, ranking equally with existing unsecured debt and senior to subordinated debt, but are effectively subordinated to secured debt and structurally subordinated to subsidiary debt. The net proceeds from this offering are earmarked for general corporate purposes. This can include strategic initiatives such as acquisitions, debt repayment or refinancing, working capital needs, capital expenditures, or equity repurchases. The company may also temporarily invest the proceeds in liquid investments until their intended use. The issuance, governed by a base indenture and a supplemental indenture, includes standard provisions for redemption, a change of control offer to purchase, and limited negative covenants that restrict the incurrence of secured debt and sale-leaseback transactions involving principal properties, as well as limits on mergers and asset sales.

Key Highlights

  • 1Thermo Fisher Scientific raised approximately $2.5 billion in net proceeds from the public offering of senior notes.
  • 2The offering includes three tranches: $1B of 5.000% notes due 2026, $1B of 5.000% notes due 2029, and $500M of 5.200% notes due 2034.
  • 3Proceeds are intended for general corporate purposes, potentially including acquisitions, debt refinancing, working capital, and capital expenditures.
  • 4The notes are unsecured general obligations, ranking equally with existing unsecured debt but subordinated to secured debt.
  • 5Redemption options are available for the company, including 'par call' provisions before maturity and full redemption at 100% of principal after a specified date.
  • 6A change of control event, coupled with a ratings downgrade, may trigger an offer to purchase the notes at 101% of the principal amount.
  • 7The indenture includes limited covenants restricting secured debt and sale-leaseback transactions on 'Principal Properties'.

Frequently Asked Questions

Thermo Fisher Scientific intends to use the net proceeds from this offering for general corporate purposes. This broad category may encompass strategic initiatives such as acquiring companies or businesses, repaying or refinancing existing debt, funding working capital needs, making capital expenditures, or repurchasing the company's outstanding equity securities. The company may also temporarily invest the proceeds in short-term, liquid investments until they are deployed for their ultimate purpose.

The company issued $1 billion of 5.000% Senior Notes due 2026, $1 billion of 5.000% Senior Notes due 2029, and $500 million of 5.200% Senior Notes due 2034. These notes are general unsecured obligations of Thermo Fisher Scientific. Interest is paid semi-annually, with specific payment dates varying by tranche (June 5 and December 5 for 2026 notes; January 31 and July 31 for 2029 and 2034 notes).

The senior notes are general unsecured obligations of Thermo Fisher Scientific. They rank equally in right of payment with the company's existing and any future unsecured and unsubordinated indebtedness. They also rank senior to any existing or future subordinated indebtedness. However, they are effectively subordinated to any existing or future secured indebtedness to the extent of the assets securing that debt. Furthermore, they are structurally subordinated to all existing and future indebtedness and liabilities of the company's subsidiaries.

In the event of a change of control of the company, accompanied by a downgrade of the notes' rating by at least two major credit rating agencies (Moody's, S&P, Fitch) below investment grade, Thermo Fisher Scientific may be required to offer to purchase the notes at 101% of their principal amount, plus accrued interest. The Indenture also outlines events of default, such as payment defaults, covenant breaches, or bankruptcy, which could lead to the acceleration of the entire principal amount of the notes becoming immediately due and payable.